IMT Header

Cambridge Healthtech Institute’s 3rd Annual
Immunomodulatory Therapeutic Antibodies for Cancer
The Evolution of the PD-1 Axis, Emerging Immunotherapy Targets and Indications, Developing Multifunctional Antibody Immunotherapies
August 24-25


Recent regulatory approvals and a succession of favorable clinical data from the checkpoint inhibitor programs of major pharmas are now spearheading a new focus on immune system-modulating antibody therapeutics.  These results are now driving interest across academic and industry research into a next generation of checkpoint blockades and co-stimulatory factors, and the application of these to additional tumor types and in exciting new roles in combination treatment regimens.  For 2015, CHI’s Third Annual Immunomodulatory Therapeutic Antibodies for Cancer will explore developments in mainstream and emerging targets in this space, review progress in the application of immunotherapy for difficult to treat cancers and consider different concepts for developing multifunctional antibody immunotherapies.

Then, with this meeting as a foundation, the following ImVacS conference, Rational Combination Cancer Immunotherapy, will review strategies for combining immune-modulating antibodies with traditional and experimental therapeutics for improved clinical benefit to patients.


PD-1 PATHWAY INHIBITORS 

Opening Keynote Presentation: PD-1 Blockade: Current Status and Future Opportunities

Michael B. Atkins, M.D., Deputy Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Current Insights on the PD-1/PD-L1 Axis as a Therapeutic Target in Oncology: A Biomarkers Perspective

Kurt Schalper, M.D., Ph.D., Associate Research Scientist, Pathology, Yale University School of Medicine

Intellectual Property Review of Major Immunotherapy Targets: Non Composition of Matter Approaches to Developing Unique IP in Cancer Immunotherapy

Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP


EMERGING INDICATIONS 

New and Noteworthy Solid Tumor Indications for Checkpoint Inhibitors

Amit Mahipal, M.D., Medical Director, Clinical Research Unit, Assistant Member, H. Lee Moffitt Cancer Center & Research Institute

Checkpoint Blockade Antibodies as a Novel Immunotherapeutic Approach in Multiple Myeloma

Gullu Topal Gorgun, Ph.D., Senior Research Scientist, Dana-Farber Cancer Institute


EMERGING TARGETS, PATHWAYS AND MECHANISMS 

Metabolomics and Regulation of T Cell Differentiation and the Anti-tumor Response

Susan Kaech, Ph.D., Associate Professor, Immunobiology, Yale University School of Medicine

Immunomodulatory Antibody Targets on Tregs

Sriram Sathy, Ph.D., Director, Target and Biomarker Discovery, Jounce Therapeutics

Endothelial Cell Regulation to Improve T Cell Extravasation

Andrea Facciabene, Ph.D., Research Assistant Professor, Obstetrics and Gynecology, University of Pennsylvania School of Medicine

Anti-Tumor Function of an Anti-iNKT TCR Monoclonal Antibody

Weiming Yuan, Ph.D., Assistant Professor, Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California

Immunomodulatory Antibody Targets on TILs

Laszlo Radvanyi, Ph.D., CSO, Lion Biotechnologies

Immunomodulatory Antibody Targets in the Tumor Microenvironment

Paul D. Rennert, Founder & Principal, SugarCone Biotech Consultants LLC


MULTIFUNCTIONAL ANTIBODY IMMUNOTHERAPIES 

Design and Construction of Tri- and Tetra-Specific Ig Molecules to Regulate T Cell Functions and Immune Responses

Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center

Multivalent Antibody Therapeutics for Cancer Immunotherapy

Charles L. Sentman, Ph.D., Professor of Microbiology and Immunology, Director, Center for Synthetic Immunity, Geisel School of Medicine, Dartmouth College

Bispecific Antibody Targeting PD-L1 and cMet

Barbara Swanson, Ph.D., Director, Research, Sorrento Therapeutics, Inc.

Bispecific Antibodies Targeting Checkpoint Inhibitors

Mark Throsby, Ph.D., CSO, Merus, The Netherlands

Talk Title to be Announced

Jacqueline Doody, Vice President, Immunology, F-star Biotechnology Ltd., United Kingdom


For more details on the conference, please contact:
Kent Simmons
Conference Director
Cambridge Healthtech Institute
T: (+1) 207-869-9199
E: ksimmons@healthtech.com  

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com